ATE466577T1 - Behandlung von krankheiten, die durch hpv verursacht werden - Google Patents

Behandlung von krankheiten, die durch hpv verursacht werden

Info

Publication number
ATE466577T1
ATE466577T1 AT02714948T AT02714948T ATE466577T1 AT E466577 T1 ATE466577 T1 AT E466577T1 AT 02714948 T AT02714948 T AT 02714948T AT 02714948 T AT02714948 T AT 02714948T AT E466577 T1 ATE466577 T1 AT E466577T1
Authority
AT
Austria
Prior art keywords
hpv
illnesses caused
treating illnesses
inhibitor
protein
Prior art date
Application number
AT02714948T
Other languages
English (en)
Inventor
Andrew Dannenberg
Kotha Subbaramaiah
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of ATE466577T1 publication Critical patent/ATE466577T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02714948T 2001-05-03 2002-03-14 Behandlung von krankheiten, die durch hpv verursacht werden ATE466577T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28810701P 2001-05-03 2001-05-03
PCT/US2002/005108 WO2002089790A1 (en) 2001-05-03 2002-03-14 Treatment of hpv caused diseases

Publications (1)

Publication Number Publication Date
ATE466577T1 true ATE466577T1 (de) 2010-05-15

Family

ID=23105762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714948T ATE466577T1 (de) 2001-05-03 2002-03-14 Behandlung von krankheiten, die durch hpv verursacht werden

Country Status (6)

Country Link
US (1) US7183316B2 (de)
EP (1) EP1390026B1 (de)
AT (1) ATE466577T1 (de)
CA (1) CA2440017A1 (de)
DE (1) DE60236273D1 (de)
WO (1) WO2002089790A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101438A1 (en) * 2002-05-30 2003-12-11 Pharmacia & Upjohn Company Treatment for human papillomavirus
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
FR2854078B1 (fr) * 2003-04-28 2008-01-11 Univ Toulouse Procede de fabrication d'une composition therapeutique immuno-stimulante.
EP2236131A3 (de) 2003-07-01 2011-03-02 President and Fellows of Harvard College SIRT1 Modulatoren zur Veränderung der Lebensdauer/Stressreaktion von Zellen/Organismen
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
CN1308036C (zh) * 2005-03-28 2007-04-04 浙江大学医学院附属妇产科医院 一种hpv多肽疫苗及其制备方法
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US9066951B2 (en) * 2008-05-29 2015-06-30 Wisconsin Alumni Research Foundation Drugs to treat HPV infection
US20130158077A1 (en) * 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
EP3074028B1 (de) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Aktivitätsverstärkende curcumin-zusammensetzungen und verfahren zur verwendung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079262A (en) * 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
US6218373B1 (en) * 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6458940B2 (en) * 1995-06-06 2002-10-01 Hybridon, Inc. HPV-specific oligonucleotides
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
EP1977749A1 (de) * 1996-10-15 2008-10-08 G.D. Searle LLC Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
JP3213557B2 (ja) 1996-11-18 2001-10-02 三井農林株式会社 茶カテキンを有効成分として含有する尖圭コンジローマ治療剤
DE69931055T2 (de) 1998-09-08 2006-12-07 Cornell Research Foundation, Inc. Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
WO2002085327A2 (en) * 2001-04-18 2002-10-31 Oraltech Pharmaceuticals, Inc. Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract

Also Published As

Publication number Publication date
CA2440017A1 (en) 2002-11-14
US20020164385A1 (en) 2002-11-07
EP1390026B1 (de) 2010-05-05
US7183316B2 (en) 2007-02-27
EP1390026A4 (de) 2006-02-22
DE60236273D1 (de) 2010-06-17
WO2002089790A1 (en) 2002-11-14
EP1390026A1 (de) 2004-02-25

Similar Documents

Publication Publication Date Title
ATE466577T1 (de) Behandlung von krankheiten, die durch hpv verursacht werden
NO20045065L (no) Nytt formatsalt av o-desmetyl-venlafaxin
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
NO20055173L (no) Farmasoytisk kombinasjonsblanding omfattende modafinil og et annet legemiddel
MXPA04001912A (es) Aminobenzofenonas novedosas.
AR036697A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
ATE421357T1 (de) Entzündungshemmende arzneizubereitungen zur entzündungsverminderung und die therapie oder die prophylaxe von der gastrischen toxizität
De Pokomandy et al. Argon plasma coagulation treatment of anal high‐grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2‐year prospective pilot study
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
EP1652525A4 (de) Anti-coronavirus-arzneimittel
Najima Parveen et al. Homoeopathic approach in COVID-19 pandemic condition: A review
NAKAJIMA et al. Safety, tolerability, and efficacy of 5-aminolevulinic acid phosphate, an inducer of heme oxygenase 1, in combination with sodium ferrous citrate for the treatment of COVID-19 patients
NO20054700L (no) Anvendelse av et fibrat og orlistat for behandling av fedme
NO20071096L (no) Diarylmetylpiperazinderivater, fremstillinger derav og anvendelser derav
Cohn et al. Keratoacanthoma of the nasal septum secondary to ranibizumab use
Gamaleldin et al. COVID-19 treatment modalities
HRP20030701A2 (en) Natural antibodies active against hiv virus
ATE395060T1 (de) Verwendung von tenatoprazol zur behandlung von gastroösophogalem reflux
Gazal Surgical removal for khat inducible verruca vulgaris lesion of the oral mucosa
DE60305018D1 (de) Citalopram zur behandlung von bluthochdruck
GINGHINA et al. Difficulties of an hpb surgery team during the SARS-CoV-2 Pandemic
Kraevskiĭ The successes and problems in the treatment of HIV infection: a biochemist's view
Quertinmont Critical role of NKT cell-derived IL-5 and eosinophils in liver injury induced by concanavalin a in mice
Olinger et al. Filoviruses
Jeang World AIDS Day 2007: AIDS at 26, are we there yet?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties